| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.09 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.09 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.056 | 0.09 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.064 | 0.09 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.09 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.053 | 0.09 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.056 | 0.09 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.09 |